NDAOPHTHALMICSOLUTION/DROPS
Approved
Aug 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HUMORSOL (demecarium bromide) is an ophthalmic solution approved in 1959 for the treatment of glaucoma and accommodative esotropia. It is a cholinesterase inhibitor that works by increasing acetylcholine levels at the neuromuscular junction, enhancing parasympathomimetic effects in the eye. The drug reduces intraocular pressure and improves accommodation through this mechanism.
LOE Approaching
This product is in late-stage lifecycle with minimal current commercial investment; roles are likely defensive maintenance rather than growth-oriented expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
HUMORSOL offers limited career growth opportunities given its approaching loss-of-exclusivity status and minimal linked job openings. Roles in this area focus on defending market share and managing the product through decline rather than driving innovation or expansion.
Regulatory Affairs SpecialistProduct Manager
Worked on HUMORSOL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.